Appendix 4C & Activity Report for Q2 FY2026

Anagenics Limited (ASX: AN1, “Anagenics” or the “Company”) today provides an update on activities during the quarter ended 31 December 2025 (“2Q26”). The Company’s operating performance has improved significantly, and it is now trading profitably and is expected to trade profitably for FY 2026. During 2Q26, Operating Cash Outflows were $0.3m, and $0.6m for the 6 months to December 2025 a 100% impr